Progyny (NASDAQ:PGNY) Upgraded at Zacks Research

Progyny (NASDAQ:PGNY) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and set a $30.00 target price on shares of Progyny in a research note on Friday, March 6th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Canaccord Genuity Group lowered their target price on Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a report on Wednesday, March 11th. KeyCorp lowered their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Finally, Barclays lowered their target price on Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a report on Friday, March 20th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and an average price target of $27.91.

Progyny Stock Up 23.8%

Shares of NASDAQ PGNY opened at $23.72 on Thursday. Progyny has a twelve month low of $16.10 and a twelve month high of $28.75. The firm has a fifty day simple moving average of $17.87 and a 200 day simple moving average of $21.69. The company has a market capitalization of $1.86 billion, a PE ratio of 30.81, a P/E/G ratio of 1.10 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. Progyny had a net margin of 5.23% and a return on equity of 12.76%. The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. During the same quarter last year, the firm earned $0.17 earnings per share. Progyny’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities analysts expect that Progyny will post 1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 7,455 shares of company stock valued at $129,515 over the last ninety days. Insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

Several hedge funds and other institutional investors have recently bought and sold shares of PGNY. Royal Bank of Canada increased its holdings in shares of Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares in the last quarter. Amundi increased its holdings in shares of Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after acquiring an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Progyny by 37.4% during the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after acquiring an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC increased its holdings in shares of Progyny by 6.9% during the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after acquiring an additional 780 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny beat Q1 estimates, reporting $0.50 adjusted EPS versus $0.44 expected and revenue of $328.5 million versus $326.5 million forecast, helping reinforce the stock’s move higher. Progyny, Inc. Announces First Quarter 2026 Results
• Positive Sentiment: The company raised second-quarter and full-year 2026 guidance, with Q2 EPS outlook of $0.50 to $0.53 and FY2026 EPS guidance of $1.98 to $2.09, both above Wall Street estimates, which supports confidence in future earnings power. Conference call and earnings materials
• Positive Sentiment: Management said early selling-season activity and member engagement were strong, and the company highlighted continued share repurchases, with 8.8 million shares bought back since November, adding another supportive signal for investors. Progyny, Inc. Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue was still down 26.4% year over year, so while the quarter beat expectations, investors may remain focused on whether growth can stabilize after the recent decline. Progyny: Q1 Earnings Snapshot
• Neutral Sentiment: Some commentary noted concern around flat revenue guidance, which could temper the bullish reaction if investors want clearer top-line acceleration going forward. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.